Patents by Inventor Jeanine D'Armiento
Jeanine D'Armiento has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11565004Abstract: The present invention provides a method of imaging a subject's lung which comprises contacting the subject's lung with a matrix metalloproteinase inhibitor labeled with a radioisotope under conditions such that the inhibitor binds to matrix metalloproteinase in the lung, and then imaging the radiolabeled inhibitor bound to matrix metalloproteinase in the subject's lung. The invention also provides Ro 32-3555 labeled with a radioisotope.Type: GrantFiled: May 19, 2017Date of Patent: January 31, 2023Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Jeanine D'Armiento, Lynne Johnson, Monica Goldklang, Yared Tekabe
-
Publication number: 20220008401Abstract: Disclosed in certain embodiments is a method of treating a pulmonary disease comprising administering a therapeutically effective amount of a Matrix Metalloproteinase (MMP) Inhibitor to a patient in need thereof wherein the pulmonary disease is selected from the group consisting of Acute Respiratory Distress Syndrome, Acute Lung Injury and Acute Inflammatory Injury, and compositions thereof.Type: ApplicationFiled: January 29, 2020Publication date: January 13, 2022Inventor: Jeanine D'Armiento
-
Publication number: 20210008231Abstract: The present invention provides a method of imaging a subject's lung which comprises contacting the subject's lung with a matrix metalloproteinase inhibitor labeled with a radioisotope under conditions such that the inhibitor binds to matrix metalloproteinase in the lung, and then imaging the radiolabeled inhibitor bound to matrix metalloproteinase in the subject's lung. The invention also provides Ro 32-3555 labeled with a radioisotope.Type: ApplicationFiled: May 19, 2017Publication date: January 14, 2021Applicant: The Trustees of Columbia University in the City of New YorkInventors: Jeanine D'ARMIENTO, Lynne JOHNSON, Monica GOLDKLANG, Yared TEKABE
-
Publication number: 20180028493Abstract: The present invention provides methods and compositions of prophylaxis for, or for treating, chronic obstructive pulmonary disease (COPD), cancer, arthritis, skin damage, or atherosclerotic plaque rupture in a subject in need thereof, which comprise i) a statin or ii) selective serotonin reuptake inhibitor (SSRI).Type: ApplicationFiled: August 11, 2017Publication date: February 1, 2018Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Jeanine D'Armiento, Takayuki Shiomi
-
Patent number: 9750789Abstract: The present invention provides a method for treating a subject suffering from tuberculosis which comprises administering to the subject a composition comprising an amount of an inhibitor of a matrix metalloproteinase (MMP) in an amount effective to treat the subject, such that the therapeutic effect of said composition is different than the therapeutic effect attributable to the antibiotic properties of said composition. The present invention also provides a method for reducing or inhibiting destruction of lung extracellular matrix in a subject comprising administering to the subject at risk for such destruction a composition comprising an amount of an inhibitor of a matrix metalloproteinase (MMP) in an amount effective to reduce or inhibit destruction of lung extracellular matrix in the subject.Type: GrantFiled: February 17, 2012Date of Patent: September 5, 2017Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Jeanine D'armiento, Paul Elkington, Jon S. Friedland
-
Publication number: 20160310454Abstract: The present invention provides methods and compositions for treating a subject afflicted with chronic obstructive pulmonary disease (COPD) which comprise a i) a Liver X receptor (LXR) agonist, ii) a miR-33 antagonist, or iii) a TLR4/Myd88 pathway antagonist. The present invention also provides methods and compositions for use in prophylactically treating a subject for chronic obstructive pulmonary disease (COPD) which comprise i) a Liver X receptor (LXR) agonist, ii) a miR-33 antagonist, or iii) a TLR4/Myd88 pathway antagonist.Type: ApplicationFiled: December 17, 2014Publication date: October 27, 2016Inventors: Jeanine D'ARMIENTO, Piotr SKLEPKIEWICZ, Vincent LEMAITRE
-
Publication number: 20150011629Abstract: Methods for modulating the level of a chemokine in a cell by administering to a cell an effective amount of a depside or an anthocyanin are provided. More particularly, a method for modulating the level of a chemokine in a cell by administering to a cell an effective amount of a depside having the structure of formula (IV): Formula (IV) wherein R is selected from H or CH3 or an anthocyanin selected from cyanidin 3-glucoside, delphinidin 3-glucoside, or combinations thereof, or an enantiomer, optical isomer, diastereomer, N-oxide, crystalline form, hydrate, or pharmaceutically acceptable salt thereof is provided. Also provided are compounds according to Formulas I-IV, pharmaceutical compositions, unit dosage forms, and food or feed supplements containing such compounds.Type: ApplicationFiled: September 22, 2014Publication date: January 8, 2015Applicant: The Trustees of Columbia University in the City of New YorkInventors: Jeanine D'Armiento, Kurt Reynertson, Edward Kennelly, Alison Wallace
-
Patent number: 8846757Abstract: Methods for modulating the level of a chemokine in a cell by administering to a cell an effective amount of a depside or an anthocyanin are provided. More particularly, a method for modulating the level of a chemokine in a cell by administering to a cell an effective amount of a depside having the structure of formula (IV): Formula (IV) wherein R is selected from H or CH3 or an anthocyanin selected from cyanidin 3-glucoside, delphinidin 3-glucoside, or combinations thereof, or an enantiomer, optical isomer, diastereomer, N-oxide, crystalline form, hydrate, or pharmaceutically acceptable salt thereof is provided. Also provided are compounds according to Formulas I-IV, pharmaceutical compositions, unit dosage forms, and food or feed supplements containing such compounds.Type: GrantFiled: July 31, 2007Date of Patent: September 30, 2014Assignees: The Trustees of Columbia University in the City of New York, The Research Foundation of The City University of New YorkInventors: Jeanine D'Armiento, Kurt Reynertson, Edward Kennelly, Alison Wallace
-
Publication number: 20140199289Abstract: The present invention provides a method for treating a subject suffering from tuberculosis which comprises administering to the subject a composition comprising an amount of an inhibitor of a matrix metalloproteinase (MMP) in an amount effective to treat the subject, such that the therapeutic effect of said composition is different than the therapeutic effect attributable to the antibiotic properties of said composition. The present invention also provides a method for reducing or inhibiting destruction of lung extracellular matrix in a subject comprising administering to the subject at risk for such destruction a composition comprising an amount of an inhibitor of a matrix metalloproteinase (MMP) in an amount effective to reduce or inhibit destruction of lung extracellular matrix in the subject.Type: ApplicationFiled: February 17, 2012Publication date: July 17, 2014Inventors: Jeanine D'armiento, Paul Elkington
-
Publication number: 20120184517Abstract: The present invention provides, inter alia, methods and compositions for treating or ameliorating the effects of a disease characterized by altered smooth muscle contractility, such as e.g., asthma.Type: ApplicationFiled: April 30, 2010Publication date: July 19, 2012Inventors: Steven Marx, Jeanine D'Armiento, Andrew Marks
-
Publication number: 20110110885Abstract: Methods for modulating the level of a chemokine in a cell by administering to a cell an effective amount of a depside or an anthocyanin are provided. More particularly, a method for modulating the level of a chemokine in a cell by administering to a cell an effective amount of a depside having the structure of formula (IV): Formula (IV) wherein R is selected from H or CH3 or an anthocyanin selected from cyanidin 3-glucoside, delphinidin 3-glucoside, or combinations thereof, or an enantiomer, optical isomer, diastereomer, N-oxide, crystalline form, hydrate, or pharmaceutically acceptable salt thereof is provided. Also provided are compounds according to Formulas I-IV, pharmaceutical compositions, unit dosage forms, and food or feed supplements containing such compounds.Type: ApplicationFiled: July 31, 2007Publication date: May 12, 2011Inventors: Jeanine D'Armiento, Kurt Reynertson, Edward Kennelly, Alison Wallace
-
Patent number: 7309578Abstract: The present invention provides a method of treating or preventing a chronic obstructive pulmonary disease in a subject, comprising administering to said subject an amount of an agent affective to inhibit apoptosis of the subject's lung cells and thus treat or prevent chronic obstructive pulmonary disease in the subject. The present invention provides for a method of diagnosing the disease.Type: GrantFiled: February 28, 2001Date of Patent: December 18, 2007Assignee: The Trustees of Columbia University in the City of New YorkInventors: Jeanine D'Armiento, Kazushi Imai
-
Patent number: 6656461Abstract: The present invention provides a method of treating or preventing a chronic obstructive pulmonary disease in a subject, comprising administering to said subject an amount of an agent effective to inhibit apoptosis of the subject's lung cells and thus treat or prevent chronic obstructive pulmonary disease in the subject. The present invention provides for a method of identifying a compound effective to treat or prevent a chronic obstructive pulmonary disease, comprising (a) contacting lung cells from a subject having a chronic obstructive pulmonary disease with the compound and measuring the level of apoptosis of the lung cells in the presence of said compound, (b) measuring the level of apoptosis of the lung cells from the same subject in the absence of said compound, (c) comparing the level of apoptosis in step (a) with the level of apoptosis in step (b), wherein a higher level of apoptosis in step (a) indicate that the compound is effective to treat or prevent chronic obstructive pulmonary disease.Type: GrantFiled: February 29, 2000Date of Patent: December 2, 2003Assignee: The Trustees of Columbia University in the City of New YorkInventors: Jeanine D'Armiento, Kazushi Imai
-
Publication number: 20030215420Abstract: The present invention provides a method of treating or preventing a chronic obstructive pulmonary disease in a subject, comprising administering to said subject an amount of an agent affective to inhibit apoptosis of the subject's lung cells and thus treat or prevent chronic obstructive pulmonary disease in the subject. The present invention provides for a method of diagnosing the disease.Type: ApplicationFiled: May 19, 2003Publication date: November 20, 2003Inventors: Jeanine D'Armiento, Kazushi Imai
-
Patent number: 6608112Abstract: The invention provides a use of a metalloproteinase inhibitor for the preparation of a pharmaceutical composition for treating human pulmonary emphysema which comprises admixing the metalloproteinase inhibitor in an amount effective to treat human pulmonary emphysema and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition which comprises a metalloproteinase inhibitor in an amount effective to treat human pulmonary emphysema and a pharmaceutically acceptable carrier.Type: GrantFiled: October 10, 2000Date of Patent: August 19, 2003Assignee: The Trustees of Columbia University in the City of New YorkInventors: Jeanine D'Armiento, Kiran Chada